A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

BACKGROUND: Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted product-label changes. The first-generation serotonin-receptor antagonist granisetron is available in oral (PO), intravenous (IV), and transdermal formulations. APF530 is a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, Jay W, Moon, Thomas E, O’Boyle, Erin, Dietz, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970917/
https://www.ncbi.nlm.nih.gov/pubmed/24741326
http://dx.doi.org/10.2147/CMAR.S58071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970917/
https://www.ncbi.nlm.nih.gov/pubmed/24741326
http://dx.doi.org/10.2147/CMAR.S58071

Ejemplares similares